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autophagy contributed to the mechanism of increased cell death. 
Additionally, ABT-888 increased tumor growth delay at well-toler-
ated doses in murine models. For a 5-fold increase in tumor volume, 
tumor growth delay was 1 day for ABT-888 alone, 7 days for radiation 
alone, and 13.5 days for combination treatment. Immunohistochemical 
staining of tumor sections revealed an increase in TUNEL apoptotic 
staining, and a decrease in Ki-67 proliferative staining after combina-
tion treatment. Matrigel assay showed a decrease in in vitro endothelial 
tubule formation with ABT-888/radiation combination treatment, and 
von Willebrand factor staining of tumor sections revealed decreased 
vessel formation in vivo, suggesting this strategy may also target tumor 
angiogenesis. 
Conclusions: We conclude that PARP-1 inhibition shows promise as 
an effective means of enhancing tumor sensitivity to radiation, and 
future clinical studies are needed to determine the potential of ABT-888 
as a radiation enhancer.
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Effect of nebulization and development of an animal model sensi-
tive to cetuximab
Background: Inhalation is a very attractive and promising route to 
deliver chemotherapy to lung tumours. Indeed, it may increase anti-
tumour responses to drugs by targeting lungs directly and may reduce 
secondary organ toxicity. Although recombinant antitumour antibodies 
are efﬁcient and exciting new therapeutics, they have never been tested 
in lung cancer treatment through airway conduction. Cetuximab, an in-
hibitory anti-EGFR (Epidermal Growth Factor Receptor) antibody, cur-
rently tested in clinical trials for non-small cell lung cancer (NSCLC) 
treatment by i.v. injection, was chosen in that purpose. In this study, we 
evaluated cetuximab nebulization and established an animal model of 
broncho-pulmonary tumour sensitive to this antibody. 
Methods: Cetuximab was nebulized with IA-1C MicroSprayer™ 
(PennCentury Inc., USA) connected to a FMJ-250 high pressure 
syringe (PennCentury Inc., USA), a device used to administrate aerosol 
in mice. The effect of nebulization on cetuximab was assessed in terms 
of its afﬁnity for membrane EGFR (using ﬂow cytometry), inhibition 
of cell growth and inhibition of EGFR phosphorylation. Tolerance to 
cetuximab delivered through airways was studied in mice. Cetuximab 
was injected either by i.p. bi-weekly (1mg) or by endotracheal spray 
using MicroSprayer™ once a week (1mg or 2.125mg). The mice were 
observed bi-weekly and monitored for signs of wound healing distur-
bance, and organ toxicity was determined post-mortem. To establish an 
animal model, we chose A431 cells, a line sensitive to EGFR inhibitors 
and used as reference in cetuximab studies. For intrabronchial tumour 
implantation, A431 cells (2 or 5. 106 cells) were injected endotrache-
ally with or without EDTA (10mM) or BDTM PuraMatrixTM Peptide 
Hydrogel in nude mice. After 6 weeks, mice were sacriﬁed and the 
number of tumour nodules in lungs was determined by histological 
examination.
Results: Firstly, our results showed that MicroSprayer™ did not alter 
cetuximab integrity, immunological and pharmacologic properties. 
Secondly, airway administration of cetuximab in mice seemed to be 
well-tolerated and did not induced additional toxicity in lungs, kidney, 
colon, skin, liver or spleen. Finally, addition of EDTA seemed critical 
for A431 tumour implantation in lungs.
Conclusion: The validation of our experimental system will allow us 
to compare cetuximab antitumour response by systemic and inhaled 
routes; and thus, to deﬁne the potential of aerosol for antitumour anti-
body administration in NSCLC.
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Background: Motexaﬁn gadolinium (MGd, Xcytrin®) is a tumor-selec-
tive anti-cancer agent that oxidizes intracellular reducing metabolites 
to generate reactive oxygen species (ROS). MGd was found to prolong 
time to neurologic progression in patients with brain metastases from 
non-small cell lung cancer (NSCLC) in a randomized trial comparing 
whole brain radiation (WBRT) plus MGd to WBRT alone. Single agent 
anti-tumor activity has been seen in several ongoing phase 1 and 2 tri-
als including NSCLC.
Methods: A549 human lung cancer cell line was used for these 
experiments. Cells were cultured in medium with or without glucose. 
Mitochondrial DNA deﬁcient A549 cells were prepared by passaging in 
medium containing ethidium bromide. Free intracellular zinc was mea-
sured using FluoZin-3™ and ﬂow cytometry. A lipoate reduction assay 
was used to determine effect on cellular bioreductive capacity, which is 
known to be affected by redox stress and zinc levels. Cellular respira-
tion was measured using a Clark electrode (Oxytherm™). Knockdown 
of antioxidant enzymes was obtained by transient transfection with 
small hairpin RNA sequences complementary to the target RNA. 
Results: In vitro treatment with MGd and physiologically relevant 
levels of zinc led to synergistic increases of free intracellular zinc 
levels and cytotoxicity. MGd cytotoxicity was found to be increased by 
using spent medium or medium deﬁcient in glutamine and or glucose 
suggesting disruption of metabolism. MGd and zinc inhibited the biore-
ductive capacity of cells as measured by effects on reduction of lipoate. 
These effects were further potentiated by mitochondrial inhibitors, 
under hypoxic conditions, and in A549 cells deﬁcient in mitochondrial 
DNA. In these cells, exposure to 10 μM MGd led to a 2.5 fold increase 
in intracellular free Zn measured by FluoZin-3 ﬂuorescence after 4 
hr. A549 cell oxygen consumption was decreased by 20% in spent 
medium after 18 hr treatment. Knockdown of the NRF-2 transcription 
factor, which controls cellular response to oxidative stress, led to 50% 
decrease in protein levels of thioredoxin reductase 1 and glutathione 
reductase. MGd and zinc treatment inhibited bioreductive capacity to 
a greater degree following NRF-2 knockdown as compared to control, 
non-targeting shRNA.
Conclusions: NRF-2 antioxidant response has been reported to be 
associated with poor prognosis and resistance to therapy in NSCLC. 
MGd is a redox cycling anti-cancer agent that causes redox stress 
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and an increase in free zinc. Redox stress is thought to affect many 
intracellular metabolic processes including inhibition of reductases and, 
ultimately, induction of cell death. Oxidative stress induced by MGd 
appears to exceed the NRF-2 mediated antioxidant capacity in A549 
lung cancer cells. The mechanism of action and activity of MGd may 
be particularly well suited for therapy of NSCLC.
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Background: Cyclooxygenase-2 (COX-2) overexpression may 
mediate resistance to EGFR TK inhibition through prostaglandin E2 
(PGE2)-dependent promotion of epithelial to mesenchymal transition 
(EMT). The suppression of epithelial markers such as E-cadherin can 
to non-small cell lung cancer (NSCLC) resistance to erlotinib. In addi-
tion, PGE2 can downregulate E-cadherin expression by upregulating 
the transcriptional repressors of E-cadherin, ZEB1 and Snail. These 
ﬁndings suggest that COX-2 inhibition may enhance the efﬁcacy of 
EGFR TKI therapy in NSCLC, and markers of EMT may be important 
in predicting response to this combination of targeted therapy. 
Methods: A phase I, dose escalation trial to was performed investigat-
ing the combination of celecoxib and erlotinib in patients with ad-
vanced NSCLC. Soluble E-cadherin was evaluated by ELISA in patient 
serum at baseline and weeks 4 and 8 of treatment. Other markers of 
COX-2 gene expression and EMT were evaluated by ELISA, including 
matrix metalloproteinase (MMP)-9, MMP-2, tissue inhibitor of MMP 
(TIMP1), and CCL15. 
Results: 22 patients had serum samples available for evaluation. Serum 
E-cadherin, MMP-9, MMP-2, TIMP1 and CCL15 were analyzed 
according to best response (PR, SD or PD). We found a signiﬁcant 
decrease in soluble E-cadherin between baseline and week 8 in pts with 
PR when compared to those with SD or PD (p = 0.021). In patients 
who responded to the combination therapy, baseline MMP-9 was sig-
niﬁcantly lower compared to non-responders (p = 0.006). MMP-2 and 
TIMP1 showed no signiﬁcant change based on patient response, and 
CCL15 decreased in patients with PR. 
Conclusions: Soluble E-cadherin, MMP-9 and other downstream 
markers of COX-2 gene expression may be useful for assessing 
response to combination celecoxib and erlotinib in pts with advanced 
NSCLC. A randomized Phase II trial is planned comparing erlotinib 
and celecoxib with erlotinib plus placebo in advanced NSCLC, to 
evaluate the efﬁcacy of this combination therapy and to assess these 
and other biomarkers in both serum and tumor tissue. 
Supported by Phase One Foundation Award, UCLA Lung Cancer 
SPORE NCI P50 CA 90388 and GLAVAHS CDA. 
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Objective: To compare the difference of only 131I-chTNT and 
combined 131I-chTNT and external irradiation for solid tumors in the 
mouse. 
Methods: chTNT-3, a chemic monoclonal antibody directed cell 
nucleus in the necrotic parts of tumor, can play important roles in many 
tumors. chTNT-3 is iodinated with 131I. Among twenty-four nude mice 
with tumor cells xenografts(human adenocarcinoma of lung) used in 
the study, were divided into six groups and given different treatment 
protocols. Total accumulated dose, 24h percentage of injected activity 
per gram of tumor tissue and accumulated dose per injected activity 
were compared between there different groups. 
Results: In the study, better yields in terms of total accumulated dose, 
24h percentage of injected activity per gram of tumor tissue and accu-
mulated dose per injected activity were seen in the ﬁrst group. 
Conclusions: Enhanced effects can be achieved by combined external 
irradiation with radioimmunotherapy using the monoclonal anticyto-
keratin antibody 131 I-chTNT. 20Gy of external irradiation should be 
given prior to Mab injection.
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Objective: To evaluate the anticancer effect of s VEGFR1 transducted 
by sendai virus using dendritic cells(DCs) as vector in vitro and in vivo
Methods: Isolated and puriﬁed mouse bone marrow derived DCs were 
infected by sendai viruses at different moi, which were transducted by 
s VEGFR1(s VEGFR1-SeV-DCs). The culture medium was collected 
to treat HUVEC in vitro to analysis the proliferation, apoptosis, s 
VEGFR1-SeV-DCs were injected to Lewis lung cancer bearing mice to 
evaluate the survival time, growth and metastasis in vivo.
Results: s VEGFR1-SeV-DCs inhibited the proliferation of HUVEC, 
and induced apoptosis in vitro, s VEGFR1-SeV-DCs inhibited the 
growth and metastasis of Lewis lung cancer in vivo, and inhibited 
proliferation of lung cancer, induced apoptosis of cancer cells and 
inhibited the angiogenesis and improved immunological response.
Conclusions: SeV-DC was an effective vector in immuno-gene 
therapy, s VEGFR1 was an interesting gene in gene therapy, it is need 
to be studied further in future.
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At present study, we evaluated an antitumor potential of low- dose che-
motherapy combined with intratumoral dendritic cells (DC) vaccine in 
the s.c. murine Lewis lung cancer model. The dose of chemotherapeu-
